Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2018

Conditions
Bone; Disorder, Development and Growth
Interventions
DRUG

Combined Oral Contraceptive

The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.

DRUG

Transdermal Contraceptive

The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.

DRUG

Contraceptive Vaginal Ring

The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.

Trial Locations (1)

16802

Women's Health and Exercise Laboratories, The Pennsylvania State University, University Park

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Purdue University

OTHER

lead

Penn State University

OTHER

NCT02367833 - Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis | Biotech Hunter | Biotech Hunter